Compare · NVO vs OMER
NVO vs OMER
Side-by-side comparison of Novo Nordisk A/S (NVO) and Omeros Corporation (OMER): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and OMER operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $167.46B, about 170.2x OMER ($983.7M).
- NVO has been more active in the news (9 items in the past 4 weeks vs 5 for OMER).
- NVO has more recent analyst coverage (25 ratings vs 14 for OMER).
- Company
- Novo Nordisk A/S
- Omeros Corporation
- Price
- -
- -
- Market cap
- $167.46B
- $983.7M
- 1M return
- -4.16%
- -
- 1Y return
- -20.63%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2009
- News (4w)
- 9
- 5
- Recent ratings
- 25
- 14
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Omeros Corporation
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN), atypical hemolytic uremic syndrome (aHUS), and COVID-19; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consist of PPAR? (OMS405) to treat opioid and nicotine addiction; PDE7 (OMS527) for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Latest NVO
- Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest OMER
- Omeros Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Omeros Corporation Reports Third Quarter 2026 Financial Results
- Omeros Corporation to Announce Third Quarter Financial Results on November 16, 2026
- Chairman, CEO & President Demopulos Gregory A Md was granted 500,000 performance stock options (SEC Form 4)
- Omeros Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA
- VP, Finance & CAO Borges David J. exercised 20,000 shares at a strike of $9.51 and sold $419,000 worth of shares (20,000 units at $20.95) as part of a pre-agreed trading plan (SEC Form 4)
- Omeros upgraded by Cantor Fitzgerald with a new price target
- VP, General Counsel Cancelmo Peter B exercised 50,000 shares at a strike of $2.94 and sold $929,668 worth of shares (50,000 units at $18.59) (SEC Form 4)
- Director Hanish Arnold C sold $282,094 worth of shares (15,000 units at $18.81) and exercised 15,000 shares at a strike of $15.23 (SEC Form 4)